Hyperpyrexia After Rectal Misoprostol Administration-A Rare Side Effect of Misoprostol: Case Report Misoprostol and Hyperpyrexia
Novelty in Biomedicine,
Vol. 10 No. 1 (2022),
31 January 2022
,
Page 89-92
https://doi.org/10.22037/nbm.v10i1.33775
Abstract
Background: Misoprostol is a safe drug that is one of the prostaglandins analogs. It has uterotonic solid potential and is good for postpartum hemorrhage (PPH). Misoprostol has some side effects; hyperpyrexia is a rare side effect after misoprostol administration.
Cases Report: A 21-year- woman, Gravid 1 Parity 1, 18 hours after cesarean section, suffered from uterus atony
and vaginal bleeding that rectal misoprostol was administered. Her PPH was managed with misoprostol and other uterotonics. She developed a fever, and because of the Coronavirus disease (covid-19) pandemic, we suspected it and assayed it, but it was negative.
Conclusion: In this rare case, hyperpyrexia occurred after rectal misoprostol administration because of dose and prostaglandin effect on the hypothalamus. In this critical situation that covid-19 is pandemic, we suggest to
specialists that keep in mind fever and hyperpyrexia may occur consequently the misoprostol administration.
- Misoprostol, Hyperpyrexia, Temperature, Covid-19, Case report
How to Cite
References
Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. New England Journal of Medicine. 2001;344(1):38-47.
Tang O, Gemzell‐Danielsson K, Ho P. Misoprostol: pharmacokinetic profiles, effects on the uterus and side‐effects. International Journal of Gynecology & Obstetrics. 2007;99:S160-S7.
Aronsson A, Bygdeman M, Gemzell‐Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Human reproduction. 2004;19(1):81-4.
Kotsonis F, Dodd D, Regnier B, Kohn F. Preclinical toxicology profile of misoprostol. Digestive diseases and sciences. 1985;30(11):142S-6S.
Henriques A, Lourenço AV, Ribeirinho A, Ferreira H, Graça LM. Maternal death related to misoprostol overdose. Obstetrics & Gynecology. 2007;109(2):489-90.
Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994–2006. American journal of obstetrics and gynecology. 2010;202(4):353. e1-. e6.
Organization WH, UNICEF. Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA, and the World Bank: Geneva: World Health Organization; 2007.
Organization WH. The World health report: 2005: make every mother and child count: World Health Organization; 2005.
Chong Y, Chua S, El-Refaey H, Choo W, Chanrachakul B, Tai B, et al. Postpartum intrauterine pressure studies of the uterotonic effect of oral misoprostol and intramuscular syntometrine. British Journal of Obstetrics and Gynaecology. 2001;108(1):41-7.
Allen R, O’Brien BM. Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics and gynecology. 2009;2(3):159.
Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum hemorrhage with misoprostol. International Journal of Gynecology & Obstetrics. 2007;99:S198-S201.
Hofmeyr GJ, Gülmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bulletin of the World Health Organization. 2009;87:666-77.
Khan R-U, El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstetrics & Gynecology. 2003;101(5):968-74.
Durocher J, Bynum J, León W, Barrera G, Winikoff B. High fever following postpartum administration of sublingual misoprostol. BJOG: An International Journal of Obstetrics & Gynaecology. 2010;117(7):845-52.
Patted SS, Goudar SS, Naik VA, Bellad MB, Edlavitch SA, Kodkany BS, et al. Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India. The Journal of Maternal-Fetal & Neonatal Medicine. 2009;22(1):24-8.
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of General Internal Medicine. 2020:1-5.
- Abstract Viewed: 268 times
- pdf Downloaded: 6243 times